Clinical usefulness of second-generation antipsychotics in treating children and adolescents diagnosed with bipolar or schizophrenic disorders

Pediatric Drugs

Volumn 13, Issue 5, 2011, Pages 291-302

  Gentile, Salvatore ^a  

^a ASL Salerno   (Italy)

Author keywords

Adolescents; Antipsychotics; Aripiprazole; Bipolar disorders; Children; Clozapine; Olanzapine; Quetiapine; Risperidone; Ziprasidone.

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; LITHIUM; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; ZIPRASIDONE;

AFFECTIVE PSYCHOSIS; AKATHISIA; BIPOLAR DISORDER; BIPOLAR I DISORDER; CONSTIPATION; DISEASE EXACERBATION; DIZZINESS; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; FAMILY RELATION; FATTY LIVER; HEMATOLOGIC DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPROLACTINEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; LONG TERM CARE; MANIA; METABOLIC DISORDER; METABOLIC SYNDROME X; METHODOLOGY; MONOTHERAPY; MUSCLE HYPERTONIA; OCULOGYRIC CRISIS; ONSET AGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOCIAL ADAPTATION; SOMNOLENCE; SUPPORT GROUP; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREMOR; WEIGHT GAIN;

EID: 80052430398     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/11591250-000000000-00000     Document Type: Review

References (71)

1. Homburger A. Vorlesungen über psychpathologie des kindersalters. Berlin: Springer, 1926
2. Hafner H, van derHeiden W. Epidemiology of schizophrenia. Can J Psychiatry 1997; 42: 139-51 (Pubitemid 27181944)
3. Hafner H, Nowotny B. Epidemiology of early-onset schizophrenia. Eur Arch Clin Neurosci 1995; 245: 80-92
4. Madaan V, Dvir Y, Wilson DR. Child and adolescent psychiatry: pharmacological approach. Expert Opin Pharmacother 2008; 9 (12): 2053-68
5. Masi G, Mucci M, Pari C. Children with schizophrenia: clinical picture and pharmacological management. CNS Drugs 2006; 20 (10): 841-66 (Pubitemid 44484247)
6. Harris M, Henry L, Harrigan S. The relationship between the duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res 2005; 79: 85-93 (Pubitemid 41362596)
7. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65: 28-37
8. Pencer A, Addington J, Addington D. Outcome of a first episode of psychosis in adolescence: a 2-year follow-up. Psychiatr Res 2005; 33: 35-43
9. Luby JL, Tandon M, Belden A. Preschool bipolar disorder. Child Adolesc Psychiatric Clin N Am 2009; 18: 391-403
10. Youngstrom EA, Birmaher B, Findling RL. Pediatric bipolar disorder: validity, phenomenology, and recommendations for diagnosis. Bipolar Disord 2008; 10: 194-214
11. Moreno C, Laje G, Blanco C, et al. National trends in the outpatients diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 2007; 64 (9): 1032-9 (Pubitemid 47360848)
12. McClellan J, Kowatch R, Findling RL. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2007; 46 (1): 107-25
13. Axelson D, Birmaher B, Strober M, et al. Phenomenology of children and adolescents with bipolar spectrum disorders. Arch Gen Psychiatry 2006; 63 (10): 1139-48 (Pubitemid 44498393)
14. Nandagopal JJ, Delbello MP,Kowatch R. Pharmacological treatment of pediatric bipolar disorder. Child Adolesc Psychiatric Clin N Am 2009; 18: 455-69
15. Pathak P, West D, Martin BC, et al. Evidence-βased use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv 2010; 61 (2): 123-9
16. Lowry F. FDA expert panel approves use of atypical antipsychotic drugs in kids [online]. Available from URL: 704271 [Accessed 2009 Nov 27]
17. Pfeifer JC, Kowatch RA, DelBello MP. Pharmacotherapy of bipolar disorder in children and adolescents: recent progress. CNS Drugs 2010; 24 (7): 575-93
18. Waknine Y. FDA approves quetiapine for pediatric schizophrenia and bipolar disorder [online]. Available from URL: article/713530 [Accessed 2010 Nov 11]
19. Waknine Y. FDA approves olanzapine for pediatric schizophrenia and bipolar disorder [online]. Available from URL: article/713484 [Accessed 2010 Nov 11]
20. Therapeutics Initiative, Evidence Based Drug Therapy. Increasing use of newer antipsychotics in children: a cause of concern? Ther Lett 2009 Apr-Jun: 74 [online]. Available from URL: newer-antipsychotics-children-cause-concern [Accessed 2011 Jul 6]
21. Il network di Pagine Sanitarie. Monografia di risperdal 60CPR 4mg Verdi [online]. Available from URL: monografia%20di%20RISPERDAL%2060CPR%204MG%20VERDI. htm [Accessed 2011 Jul 7]
22. Il network di Pagine Sanitarie. Monografia di Abilify IM FL 1,3ML 7,5MG ML [online]. Available from URL: maci/monografia%20di%20ABILIFY%20IM%20FL%201, 3ML%207,5MG% 20ML.htm [Accessed 2011 Jul 6]
23. Piscitelli SC, Frazier JA,McKenna K, et al. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 1994; 55 (9 Suppl. B): 94-7 (Pubitemid 24353027)
24. Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of childhoodonset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007; 46 (10): 1349-56 (Pubitemid 47462194)
25. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric disorder, manic or mixed episode, with aripiprazole: a randomized, doubleblind, placebo-controlled trial. J Clin Psychiatry 2009; 70 (10): 1441-51
26. Gentile S. Contributing factors to weight gain during long-term treatment with second-generation antipsychotics: a systematic appraisal and clinical implications. Obesity Rev 2009; 10 (5): 527-42
27. Tramontina S, Zeni CP, Ketzer CR, et al. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized trial. J Clin Psychiatry 2009; 70 (5): 756-64
28. Tohen M, Kryshanovskaya L, Carlson G, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007; 164: 1547-56 (Pubitemid 350069734)
29. Delbello M, Kowatch RA, Adler CM, et al. A double-βlind randomized pilot study comparing quetiapine and divalproex for adolescentmania. J Am Acad Child Adolesc Psychiatry 2006; 45 (3): 305-13
30. Delbello M, Welge JA, Adler CM, et al. A double-βlind placebo-controlled study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disord 2009; 11: 483-93
31. Delbello M, Schwiers MS, Rosenberg HL, et al. A double-βlind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41 (10): 1216-23 (Pubitemid 38338041)
32. Haas M, Delbello M, Pandina G, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-βlind placebo-controlled study. Bipolar Disord 2009; 11: 687-700
33. Pavuluri MN, Henry DB, Findling RL, et al. Double-βlind, randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord 2010; 12: 593-605
34. Gentile S. Second-generation antipsychotics in bipolar disorder, two years later: the song remains the same. Sociedad Iberoamericana de Información Cientifica, June 2009 [online]. Available from URL: www.trabajosdistinguidos.com/smental/td-saludmental-12-2-d179.pdf. [Accessed 2011 Jul 6]
35. Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, doubleblind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008; 165 (11): 1432-41
36. Kumra S, Frazier JA, Jacobsen LK, et al. Childhood onset schizophrenia: a double-βlind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996; 53: 1090-7
37. Shaw P, Sporn A, Gogtay N, et al. Childhood onset schizophrenia: a double-βlind clozapine-olanzapine comparison. Arch Gen Psychiatry 2006; 63: 721-30
38. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and "high dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-βlind comparison. Biol Psychiatry 2008; 63: 524-9 (Pubitemid 351220784)
39. Kryshanovskaya L, Schulz C, McDoulgle C, et al. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-βlind, placebo- controlled trial. J Am Acad Child Adolesc Psychiatry 2009; 48 (1): 60-70
40. Haas M, Unis AS, Armenteros J, et al. A 6-week, randomized, double-βlind placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009; 19 (6): 611-21
41. Haas M, Eerdekens M, Kushner SF, et al. Efficacy, safety, and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-βlind study. Br J Psychiatry 2009; 194: 158-64
42. Sikich L, Frazier JA, Findling RL, et al. Double-βlind comparison of first-and second generation antipsychotics in early onset schizophrenia and schizoaffective disorders: findings from the treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS) Study. Am J Psychiatry 2008; 165: 1420-31
43. FindlingRL, Johnson JL,McClellan J, et al. Double-βlindmaintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study. J Am Acad Child Adolesc Psychiatry 2010; 49 (6): 583-94
44. McClellan J, Sikich L, Findling RL, et al. Treatment of early onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2007; 46 (8): 969-78 (Pubitemid 47220681)
45. Sikich L, Harmer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-βlind, randomized, 8-week trial. Neuropsychopharmacology 2004; 29: 133-45 (Pubitemid 38068023)
46. Word Health Organization. Clinical trials in children [online]. Available from URL: http://www.who.int/ictrp/child/en/ [Accessed 2011 Feb 15]
47. Gennery B. Clinical research in children: a pharmaceutical industry view. Paed Perinatal Drug Ther 2000; 4 (2): 35-8
48. Caldwell P, Murphy S, Butow P, et al. Clinical trials in children. Lancet 2004; 364 (9436): 803-11 (Pubitemid 39165102)
49. Crocetti MT, Amin DD, Scherer R. Assessment of the risk of bias among pediatric randomized controlled trials. Pediatrics 2010; 126 (2): 298-305
50. Gentile S. Long term atypical antipsychotics treatment and risk of weight gain: a literature analysis. Drug Saf 2006; 29 (4): 303-19
51. Gentile S. Quality of life and weight related issues in patients treated for schizophrenia: focus on aripiprazole. Neuropsychiatr Dis Treat 2009; 5: 117-25
52. Gentile S. Atypical antipsychotic for the treatment of bipolar disorder: more shadows than lights. CNS Drugs 2007; 21 (5): 367-87 (Pubitemid 46705301)
53. Dittmann RW, Meyer E, Freisleder FJ, et al. Olanzapine in male and female patients with schizophrenia and related disorders: minor sex differences in outcomes. J Clin Psychopharmacol 2010; 30 (3): 328-31
54. Calabrese JR, Keck Jr PE, Macfadden W, et al. A randomized, double-βlind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-60 (Pubitemid 40905587)
55. Thase ME, MacFadden W, Weisler RH, et al., the BOLDER II Study Group. Efficacy of quetiapine monotherapy in bipolar I and II depression: a doubleblind, placebo-controlled study (The BOLDER II Study).J Clin Psychopharmacol 2006; 26 (6): 600-9 (Pubitemid 44772737)
56. Pfizer. Safety and tolerability of ziprasidone in adolescents with schizophrenia [ClinicalTrials.gov identifier NCT00265382]. US National Institutes of Health, Clinical Trials.gov [online]. Available from URL: trials.gov/ct2/show/NCT00265382 [Accessed 2010 Mar 9]
57. Fraguas D, Correll CU, Merchán-Naranjo J, et al. Efficacy and safety of secondgeneration antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol. Epub 2010 Aug 9
58. Dickstein DP, Towbin KE, Van Der Veen JW. Randomized double-βlind placebo-controlled trial of lithium in youths with severe mood dysregulation. J Child Adolesc Psychopharmacol 2009; 19 (1): 61-73
59. Findling RL, Frazier TW, Youngstrom EA. Double-βlind, placebo-controlled trial of divalproex monotherapy in the treatment of symptomatic youth at high risk for developing bipolar disorder. J Clin Psychiatry 2007; 68 (5): 781-8 (Pubitemid 46841864)
60. Kowatch RA, Sethuraman RA, Hume JH, et al. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry 2003; 53 (11): 978-84 (Pubitemid 36645228)
61. Kowatch RA, Fristad M, Birmaher B, and the Workgroup Members. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44 (3): 213-35 (Pubitemid 40299835)
62. Yatham LN, Kennedy SH, O'Donovan C. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006; 8: 721-39 (Pubitemid 44824712)
63. Moreno C, Merchán-Naranjo J, Alvarez M, et al. Metabolic effects of second-generation antipsychotics in bipolar youths. Bipolar Disord 2010; 12: 172-84
64. Maayan LA, Vakhrushava J. Risperidone associated weight gain, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. Hum Psychopharmacol 2010; 25 (2): 133-8
65. Correll CY, Sheridan EM, DelBello MP. Antipsychotics and mood stabilizers efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomised, placebo-controlled trials. Bipolar Disord 2010; 12: 116-41
66. Panangiotopoulos C, Ronsley R, Elbe D, et al. First do not harm: promoting an evidence-βased approach to atypical antipsychotic use in children and adolescents. J Can Acad Child Adolesc Psychiatry 2010; 19 (2): 124-37
67. Gracious BL, Cook SR, Meyer AE, et al. Prevalence of overweight and obesity in adolescents with severe mental illness: a cross-sectional chart review. J Clin Psychiatry 2010; 7 (17): 949-54
68. Morrato EH, Nicol GE, Maahs D, et al. Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med 2010; 164 (4): 344-51
69. Constantine RJ, Boaz T, Tandon R. Antipsychotic polypharmacy in the treatment of children and adolescents in the fee-for-service component of a large state Medicaid program. Clin Ther 2010; 32 (5): 949-59
70. American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2001; 40: S4-23
71. Shirkey H. Therapeutic orphans. J Pediatr 1968; 72: 119-20